Mrinalini Dey
@drminidey
Clinical Research Fellow @KCLImmunoMicro•Rheumatology Registrar•@EMEUNET rep to EULAR-PARE•Editorial Board @RheumJnl•#Comorbidities #SocialDeterminantsOfHealth
ID: 1125862449280843776
https://www.researchgate.net/profile/Mrinalini_Dey 07-05-2019 20:38:20
2,2K Tweet
1,1K Followers
1,1K Following
🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. Dr. John Cush #EULAR2025 #LB0003
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability. Dr. John Cush #EULAR2025 #LB0004
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens. ⭐️🌱STAR/CRESS response rates also favoured active treatment. Safe, accessible, affordable option for active disease. Dr. John Cush #EULAR2025 #LB0005
In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS. Remission matters for subsequent Tx reduction. Dr. John Cush #EULAR2025 #LB0006
💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5). Dr. John Cush #EULAR2025 #LB0007 #CART
🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL. 💊Potential new oral ULT option. Dr. John Cush #EULAR2025 #LB0008
In a 1st-in-human trial, allogeneic CD19 CAR-NK cell therapy was safe and effective in severe refractory #SLE. No neurotoxicity or ≥G2 CRS. At 12m, 67% achieved DORIS remission, 75% LLDAS. An alternative to autologous #CART? Dr. John Cush #EULAR2025 #LB0009
APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. Dr. John Cush #EULAR2025 #LB0010
🕵🏻 Did you do the escape rooms at #EULAR2025? 🙏🏼⭐️ Huge thanks to Cristina Calomarde-Gómez & Raquel 🌼 who organised and curated this fantastic activity! 🧩🔎 Much needed downtime, educational & something different between the lectures & talks! 👏🏼 Congrats & thank you! Dr. John Cush
A pleasure to once again organise the EMEUNET X PARE speed dating, this yr expertly curated by Krystel Aouad! There was such a buzz & I was delighted to discuss #SharedDecisionMaking &treatment adherence with our fantastic patients. Thanks to all involved! #EULAR2025 Dr. John Cush
🤩So excited about this interview! 💻#LupusGPT was winning awards at #EULAR2025 🎙️Delighted to meet with Zoe & Jeanette Andersen from Lupus Europe to find out about this exciting development in patient information & use of #AI in #rheumatology Dr. John Cush youtu.be/Iq4w7pwF0f8?fe…
🦋 Thank you to Mrinalini Dey from RheumNow for this great interview on #LupusGPT & #EasyLupus! Don’t miss our Chair, Jeanette Andersen, and Zoe Karakikla-Mitsakou (General Secretary) as they reveal the story behind these innovative AI tools! youtube.com/watch?feature=…
Catch up on #RheumatoidArthritis highlights from #EULAR2025 with the Dr. John Cush round-up! A pleasure to discuss all things RA with RheumNow Royalty, Drs John Cush, Janet Pope & Jonathan Kay. Watch here: lnkd.in/dbZA2WHU Listen here: lnkd.in/dTkzKhUW
Patients with giant-cell arteritis need better treatments. This video, in partnership with Dr. Glaucomflecken, summarizes new research findings on the JAK-1 inhibitor upadacitinib in patients with giant-cell arteritis. Access the article for free: nej.md/DrG22